These innovative compounds represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://alyssafkxt184922.ezblogz.com/70700111/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide